Loading…
Loading…
PTCT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for PTCT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for PTCT and 80,000+ other tickers.
See exactly how PTCT's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTCT and 80,000+ other tickers.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for…
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total transaction of $149,025.00. Following the completion of the sale, the director directly owned 1,291,594 shares of the company's
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m.
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Boulding sold 435 shares of the company's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the sale, the vice president directly owned 105,272 shares in
Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Volatility and Risk Precigen has a beta of